8.08  0.305 (3.92%)		10-09 16:00
Open: 7.935 High: 8.11 Volume: 72,768		Pre. Close: 7.775 Low: 7.9 Market Cap: 466(M)

Short term
Mid term
Targets	6-month :	9.89	1-year :	10.46
Resists	First :	8.47	Second :	8.96
Pivot price	8.4
Supports	First :	7.67	Second :	6.38
MAs	MA(5) :	7.97	MA(20) :	8.4
	MA(100) :	7.6	MA(250) :	7.54
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	13.9	D(3) :	11.9
RSI	RSI(14): 46.7
52-week	High :	8.96	Low :	6.22

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KMDA ] has closed above bottom band by 27.4%. Bollinger Bands are 59% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	8.12 - 8.17	8.17 - 8.21
Low:	7.78 - 7.84	7.84 - 7.89
Close:	7.99 - 8.08	8.08 - 8.16

Kamada Ltd. is a biopharmaceutical firm focused on developing, manufacturing, and distributing protein therapeutics derived from human plasma. The company operates through two core business areas: its proprietary product segment and its distribution division. Its own manufactured portfolio includes KAMRAB/KEDRAB for rabies prevention, CYTOGAM to prevent cytomegalovirus disease in transplant recipients, WINRHO SDF for immune thrombocytopenic purpura and Rhesus (Rh) isoimmunization, HEPAGAM B for hepatitis B recurrence prevention following liver transplants and for post-exposure prophylaxis, VARIZIG for post-exposure chickenpox prophylaxis, and GLASSIA for intravenous alpha-1 antitrypsin deficiency (AATD). Kamada also produces KamRho (D) for the prophylaxis of hemolytic disease of newborns and immune thrombocytopenic purpura, along with a specific antiserum for Vipera palaestinae and Echis coloratus snake bites. Additionally, the company distributes a wide array of third-party pharmaceutical products, encompassing treatments like BRAMITOB for chronic pulmonary infections, FOSTER for asthma, PROVOCHOLINE for diagnosing bronchial airway hyperactivity, and specialized therapies such as IVIG for immunodeficiency, VARITECT for chickenpox and zoster herpes, and various factors for hemophilia A and B, among numerous others for conditions like hepatitis B, cytomegalovirus, angioedema, Japanese encephalitis, and prostate cancer. Kamada markets its offerings in the United States through strategic partners and internationally via a network of distributors. The company maintains significant collaborations with Takeda Pharmaceuticals Company Limited, PARI GmbH, and Kedrion Biopharma. Established in 1990, Kamada Ltd. is headquartered in Rehovot, Israel.

Tue, 06 Oct 2026
Two drug launches in Israel expand Kamada (KMDA)'s portfolio as it projects sales through 2030. - Stock Titan

Mon, 05 Oct 2026
No pre-approval inventory costs were booked as assets in 2024–25, Kamada (KMDA) says. - Stock Titan

Tue, 29 Sep 2026
Kamada (KMDA) director Ishay Davidi's previously reported options carry three adjusted exercise prices. - Stock Titan

Tue, 29 Sep 2026
A special cash dividend adjusted the exercise prices on Kamada (KMDA) director Uri Botzer’s options. - Stock Titan

Thu, 24 Sep 2026
Kamada (KMDA) HR VP receives two option awards that vest in four annual installments. - Stock Titan

Thu, 24 Sep 2026
A dividend changed the exercise prices on options acquired by a Kamada (KMDA) director. - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	58 (M)
Shares Float	33 (M)
Held by Insiders	6.9 (%)
Held by Institutions	49.1 (%)
Shares Short	209 (K)
Shares Short P.Month	157 (K)

EPS	0.37
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.65
Profit Margin	11.6 %
Operating Margin	17.3 %
Return on Assets (ttm)	4.6 %
Return on Equity (ttm)	8.3 %
Qtrly Rev. Growth	22.7 %
Gross Profit (p.s.)	1.35
Sales Per Share	3.32
EBITDA (p.s.)	0.71
Qtrly Earnings Growth	23.1 %
Operating Cash Flow	36 (M)
Levered Free Cash Flow	16 (M)

PE Ratio	21.26
PEG Ratio	0.5
Price to Book value	1.73
Price to Sales	2.43
Price to Cash Flow	13.03

Dividend	0.17
Forward Dividend	0
Dividend Yield	2.1%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.